Objective To assess the efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis (IPF), we conducted a retrospective study of patients who received pirfenidone therapy. In addition, the combined effects of inhaled N-acetylcysteine (NAC) and pirfenidone were evaluated. Methods Eligible patients had a clinical and radiologic diagnosis of advanced-stage IPF (stages of severity III&IV). Patients who exhibited a relative decline in forced vital capacity (FVC) of 10% or more within the preceding six (±2) months were enrolled. The outcome was evaluated from the date of the 6-month follow-up PFT. Relative declines in FVC of more than 10% were defined as progressive disease (ineffective group), while those less than 10% were defined as stable disease (effective group). The clinical features were compared between the two groups. We also compared the efficacy of the combined therapy with inhaled NAC and pirfenidone (n=11) with that of pirfenidone alone (n=7). Results Eighteen patients 59-82 years of age with IPF who received pirfenidone therapy were reviewed. Pirfenidone stabilized declines in FVC by 10% at six months in eight of the 18 cases (44%). The median changes in FVC at six months were +120 mL in the effective group and -590 mL in the ineffective group. The number of NAC users was significantly higher in the effective group (7/8=87.5%) than in the ineffective group (3/10=30%) (p=0.02). Furthermore, the use of combined NAC therapy was correlated with a favorable outcome. The median change in FVC at six months was 0 mL in the NAC group and -290 mL in the non-NAC group. The median survival period was 557±66 days in the NAC group and 196±57 days in the non-NAC group (p=0.03). Conclusion Among the advanced-stage IPF patients with a more progressive status, pirfenidone decreased the rate of decline in FVC. In addition, patients treated with pirfenidone combined with NAC therapy exhibited favorable outcomes. Additional studies are needed to confirm the efficacy of this combined therapy for IPF.
Introduction
It has recently been shown that decreases in the forced vital capacity (FVC) of 5-10% or more from baseline over a period of six months are associated with an increased risk of a poorer prognosis in patients with idiopathic pulmonary fibrosis (IPF) (1, 2) . Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a promising agent with therapeutic potential for treating IPF that exhibits combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Although pirfenidone preserves the FVC and improves progression-free survival better than a placebo in patients with early-stage IPF (3) (4) (5) , the effects of pirfenidone are uncertain in patients with advanced-stage IPF [stage III, IV according to the Japanese Respiratory Societyexhibits antifibrotic effects against IPF, the combined effects of pirfenidone and NAC are also uncertain. An oxidantantioxidant imbalance may contribute to the disease process observed in IPF. Therefore, it is logical to consider an antioxidant-based treatment strategy for patients with IPF. It is possible to raise the glutathione (GSH) levels in bronchoalveolar lavage fluid in patients with IPF by administering of GSH aerosols, which in turn is associated with a significant reduction in the release of oxidants by alveolar macrophages. NAC is a tripeptide (g-glutamylcysteinylglycine) that is not only a precursor of GSH, but also a direct scavenger of oxygen-free radicals. Furthermore, inhibition of transforming growth factor-β signaling or its direct modification by NAC may be beneficial in IPF, the pathogenesis of which is associated with excessive amounts of this growth factor. Therefore, inhalation of NAC may attenuate inflammation and lung fibrosis more effectively.
The aim of this study was to assess the efficacy and safety of pirfenidone monotherapy or combination therapy with inhaled NAC in patients with the deteriorated phase of advanced-stage IPF.
Materials and Methods
We conducted a retrospective study of patients with IPF who received pirfenidone therapy (1,200-1,800 mg/day) between February 2009 and September 2011. The diagnosis of IPF was made in accordance with the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society/Latin American Thoracic Association (ALAT) new IPF guidelines (6) and the fourth version of the clinical diagnostic criteria guidelines for idiopathic interstitial pneumonia in Japan (7) . Eligible patients included adults with a confident clinical and radiologic diagnosis of IPF with a severity stage classified as Stage III or Stage IV (defined as an advanced-stage), indicating that the arterial oxygen partial pressure was less than 69 torr at rest, with or without desaturation during a 6-minute walking distance (6 MWD) test, according to the JRS criteria (4) .
Of the 84 consecutive IPF patients treated during this period, 42 were diagnosed with advanced-stage disease. A total of 20 of the 42 patients who exhibited relative declines in the FVC of 10% or more within the preceding six (±2) months before the study were enrolled. Serial pulmonary function test (PFT) trends at six (±2) months, expressed as percentages of the baseline values, were evaluated for FVC. The exclusion criteria were: 1) clinical features of idiopathic interstitial pneumonia other than IPF, 2) pirfenidone therapy was not continued over one month due to of adverse events and 3) evidence of known coexisting respiratory infections, pulmonary hypertension, asthma or bronchiectasis.
Pulmonary function tests
The lung volume, forced expiratory volume in one second (FEV1.0) and carbon monoxide diffusing capacity (DLco) were measured according to standard methods using the Chestac 8,800 (Chest Co. Ltd., Tokyo, Japan) and expressed as the percent of the predicted value. The %FVC was calculated according to Baldwin's prediction formula, and % DLco was calculated according to Burrow's prediction formula.
Inhaled NAC treatment
Pretreatment for IPF was continued after the initiation of pirfenidone therapy. The NAC-treated group was treated twice daily with inhalation of 352.4 mg of NAC, diluted with saline to a total volume of 4 mL, using microair nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan).
Efficacy end points
The efficacy of pirfenidone therapy was evaluated based on the date of the 6-month follow-up PFT. Relative trends in declines of the FVC ! 10% from baseline (e.g., a 10% decline in FVC indicates a decrease from 3,000 mL to 2,700 mL) were defined as reflecting progressive disease (ineffective group), while those <10% were defined as reflecting stable disease (effective group). When the FVC data could not be obtained due to worsening of the patient's respiratory symptoms, including acute exacerbation, the case was also classified as a case of progressive disease. The clinical features were compared between these two groups. We also compared the efficacy of the combined therapy with inhaled NAC and pirfenidone in 11 patients with that of pirfenidone alone in seven patients. Acute exacerbation of IPF was defined according to the revised criteria for acute exacerbation of IPF in Japan (4).
Statistical analysis
All values were expressed as the median (minimum, maximum), and differences between subjects groups were analyzed using the Mann-Whitney nonparametric U-test or for two independent samples. Changes from the baseline values and survival were compared using the Wilcoxon test. All p values corresponded to two-sided tests and were considered to be statistically significant when less than 0.05. All analyses were performed using the SPSS statistical software package (version 13; SPSS, Inc., Chicago, IL, USA).
This retrospective study was conducted with the approval of the Institutional Review Board of Toho University Omori Medical Center (project approval number 21-64). All patients or his/her family members provided written informed consent, and the medical records were reviewed with the approval of the Institutional Review Board.
Results
Two of the 20 patients with no post-baseline data were excluded. Eighteen patients (14 men and four women, 59-82 years of age) with IPF who received pirfenidone therapy were reviewed. The patient characteristics before the initiation of pirfenidone therapy, including age, sex, smoking Pretreatment for IPF included inhaled NAC monotherapy in 10 patients, low-dose prednisolone (20 mg/day) with inhaled NAC in one patient, combination immunosuppressive treatment, including low-dose prednisolone (10-20 mg/day) with tacrolimus (2 mg/day), in two patients and none in five patients. The relative decline in FVC over the preceding six (± 2) months to the initiation of pirfenidone therapy was -15± 10.5% in the effective group and -16±4.6% in the ineffective group, although the difference was not significant. There were no differences in the frequency of acute exacerbation before pirfenidone therapy between the two groups (0 vs. 0). The percentage of patients with a <10% decline in FVC at six months after the initiation of pirfenidone therapy was 44% (8/18 cases). The median change in FVC at six months was +120 mL in the effective group (n=8) and -590 mL in the ineffective group (n=10) with the difference of 710 mL being significant (p=0.02). The relative change in FVC after six months of pirfenidone therapy was +5.5% in the effective group and -30% in the ineffective group (Fig. 1) . The clinical and laboratory parameters measured before the initiation of pirfenidone therapy, including age, the P/F ratio, the estimated pulmonary artery pressure (ePAP) and the serum damaged-pneumocyte marker levels [KL-6, surfactant protein D (SP-D), surfactant protein A (SP-A)], were not significantly different between the two groups. The baseline characteristics of the PFTs performed before the initiation of pirfenidone therapy, including the FVC, % predicted FVC, % predicted DLco and FEV1.0%, were not significantly different between the two groups ( Table 2 ). This study did not include a greater proportion of patients with obstructive airway disease, characteristics associated with a reduced decline in FVC. The daily dose of pirfenidone was not significantly different between the groups; however, the duration of pirfenidone therapy was longer in the effective group, with a significant difference (p=0.002). The doses and duration of inhaled NAC among the patients who received the combination therapy were not significantly different between the two groups. The numbers of usual interstitial pneumonia (UIP)/possible UIP/inconsistent with UIP patterns on high resolution CT (HRCT) according to the ATS/ERS/JRS/ALAT new IPF guidelines in the effective and ineffective groups were 8/0/0 and 9/1/0, respectively. There were no differences in the extent or severity of the honeycomb pattern on HRCT.
The number of NAC users was significantly higher in the effective group (7/8=87.5%) than in the ineffective group (3/ 10=30%). Furthermore, the use of the combined NAC therapy was correlated with a favorable outcome (p=0.02, r= 0.7). The rate of overall death related to IPF was lower in the effective group (zero cases) than in the ineffective group (six cases). No differences were found in the frequency of acute exacerbation following the administration of pirfenidone therapy between the two groups. The median survival period after the initiation of pirfenidone therapy was 672 days in the effective group and 244 days in the ineffective group (p=0.002).
Moreover, we analyzed the differences in the clinical characteristics between the NAC group and the non-NAC group. The clinical and laboratory parameters measured before the initiation of pirfenidone treatment, including age, the P/F ratio, ePAP and the serum damaged-pneumocyte marker levels (KL-6, SP-D, SP-A), were not significantly different between the two groups. The relative decline in FVC within the preceding six (±2) months and the baseline characteristics of the PFTs before the initiation of pirfenidone therapy were not significantly different between the two groups. The daily dose of pirfenidone was not significantly different between the two groups ( Table 3 ). The median change in FVC at six months was 0 mL in the NAC group (n=11) and -290 mL in the non-NAC group (n=7), with the difference being significant (p=0.04). The relative changes in FVC before and after six months of pirfenidone therapy increased from -15% to 0% in the NAC group and from -18% to -14.5% in the non-NAC group, with the difference being significant (p=0.05) (Fig. 2) . The median survival time was 475 days in the combined NAC and pirfenidone group and 196 days in the non-NAC group (p=0.03) (Fig. 3) . In the present study, no differences were found in the frequency of acute exacerbation between the two groups.
Although photosensitivity is a well-established major side-effect of pirfenidone, it was mild in severity in most of the patients. Four patients discontinued the therapy due to gastrointestinal discomfort, such as nausea and/or anorexia. However, most of the adverse events disappeared with a decrease in the dose or temporary withholding of the medication.
Discussion
IPF remains a progressive and fatal disease, and no treatment has been shown to be efficacious, despite several large clinical trials conducted in the past decade (8) (9) (10) (11) (12) . The results of this study demonstrated an effect of pirfenidone treatment on the change in FVC at six months in 44% of the patients, even those with advanced-stage IPF. A significantly better survival was noted in the effective group than in the ineffective group. These results imply that pirfenidone therapy may decrease the risk of a poorer prognosis in patients with advanced-stage IPF. No significant differences were noted between the effective and ineffective groups in regard to pretreatment background factors, such as age, sex, smoking history, FVC, % predicted FVC and DLco, with the exception that receiving inhaled NAC therapy was significantly higher in the effective group. The relative change in FVC before and after six months of pirfenidone therapy increased from -16% to 5.5% in the effective group and decreased from -15% to -30% in the ineffective group. These data suggest that pirfenidone may decrease the decline in FVC in some advanced-stage IPF patients with a rapidly progressive condition (decline in FVC>10% within six months before treatment). The change in FVC was selected as the primary end point due to its clinical use and the clinical relevance of irreversible loss of the lung function. Furthermore, it is a reliable, and responsive measurement of irreversible morbidity in patients with IPF and is a predictor of survival (1) (2) (3) (4) (5) . Assessing of the proportion of patients exhibiting a decrement of 5-10% or more is accepted to be clinically meaningful (1, 2) . In the analysis of the categorical FVC changes, pirfenidone therapy reduced the proportion of patients exhibiting a decrement of 10% or more. Moreover, the pirfenidone effective group demonstrated a greater reduction in the risk of death compared with the ineffective group and a consistently favorable effect on mortality.
These findings are supported by a phase 3 study of the use of pirfenidone in patients with IPF in whom the decline in vital capacity was significantly reduced at week 52 (4, 5).
Additionally, a Cochrane meta-analysis of all three phase 3 trials of pirfenidone in patients with IPF (n=1,046) showed significant improvements in progression-free survival (hazard ratio: 0.70, 95% CI: 0.56-0.88; p=0.002), an end point predominantly driven by large reductions in the lung function. Since preceding reports have enrolled patients with mild to moderate IPF and few comorbidities, these results cannot necessarily be generalized to patients with advancedstage disease. The results obtained in patients with mild to moderate IPF and our favorable results in patients with advanced-stage IPF suggest the efficacy of pirfenidone irrespective of disease severity.
The adverse events observed in this study were consistent with the known safety profile of pirfenidone, including photosensitivity and gastrointestinal events. The adverse events reported in this study were typically mild or moderate in severity, and only four patients discontinued treatment due to gastrointestinal events, such as nausea and anorexia. Data obtained from earlier multinational, double-blind, placebocontrolled phase 3 studies show clinically meaningful benefits and a favorable safety profile for pirfenidone in patients with IPF (3-5). However, six of the 10 patients in the ineffective group died due to IPF disease progression. How to treat patients in the ineffective group remains a serious problem.
In this study, therapy consisting of pirfenidone addition to NAC was correlated with a favorable outcome; therefore, combination therapy with NAC and pirfenidone may be an effective approach in treating NAC-resistant or pirfenidoneresistant IPF. The concomitant administration of inhaled NAC was generally well tolerated. Acetylcysteine is a pre- efficacy of NAC inhalation at the same dose used in this study to correlate with an improvement of the redox imbalance in IPF patients (14) . In a review of NAC trials, a placebo-controlled randomized trial comparing the effects of high-dose oral acetylcysteine versus a placebo in patients receiving prednisone plus azathioprine has been completed (10) . In that study, the 12-month declines in VC and DLco were significantly less in the acetylcysteine-treated arm. There were no observed differences in mortality or other secondary end points, including dyspnea, the quality of life, exercise physiology or radiographic appearance. Recently, Homma et al. also reported the efficacy of inhaled NAC monotherapy. Although that study did not meet the primary end point in all subjects, the post hoc analysis showed significantly lower 48-week declines in FVC (a difference of 120-170 mL) in a subset of patients with a mean baseline VC of almost 80% of the predicted value and a DLco of almost 43% of the predicted value (15) . The authors reported positive results in some IPF patients treated with inhaled NAC without the use of any immunosuppressive or anti-fibrotic agents; therefore, they anticipate that NAC will be a candidate for future therapy of IPF. The effects of NAC and pirfenidone in patients with IPF are based on completely different mechanisms; therefore, the use of combination therapy may be an effective approach. Further trials, such as those evaluating pirfenidone alone versus NAC combined with pirfenidone, are needed to serve as a guide for the development of new therapies for IPF.
Limitations
The present study was a retrospective single-center study with a small sample size. Patients who were unable to continue pirfenidone therapy over one month due to adverse events were excluded. Therefore, there is a possibility that the enrollment and exclusion criteria may have biased the results. Whether NAC-pirfenidone combination therapy translates into clinical benefits for patients in terms of the quality of life or survival has not yet been demonstrated.
Conclusion
Among advanced-stage IPF patients with more progressive disease, defined as a decline in FVC of ! 10% within six months before treatment, pirfenidone therapy may decrease the rate of decline in FVC. Since the decline in FVC is considered to be a surrogate marker of the prognosis, pirfenidone may contribute to improving the prognosis in patients with advanced-stage IPF. Therapy consisting of NAC combined with pirfenidone may be a promising treatment for improving a poor prognosis. Further large, placebocontrolled, randomized trials are needed at the various stages of IPF to confirm the efficacy of combination therapy with pirfenidone and NAC.
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